PP01.78 Brain Metastasis in Patients With KRAS Mutant Advanced NSCLC Receiving Docetaxel: Pooled Clinical Trial Data Analysis

Lung cancer is the leading cause of brain metastases (BMs). However, the risk of BM progression in KRASmut advanced NSCLC (aNSCLC) has not been well-described in clinical trial (CT) cohorts, which exclude patients with poor functional status or unstable, symptomatic BMs. This study used pooled CT data to evaluate the incidence and progression of BM in KRASmut aNSCLC CT participants (pts) treated with docetaxel (DOCE) containing regimens.